Full Press Release Details
MBX Biosciences Doses First Patient in Phase 2 Avail Trial of MBX 2109 for the Treatment of Hypoparathyroidism.
MBX
MBX Biosciences Doses First Patient in Phase 2 Avail Trial of MBX 2109 for the Treatment of Hypoparathyroidism
Key Takeaway: MBX Biosciences Doses First Patient in Phase 2 Avail Trial of MBX 2109 for the Treatment of Hypoparathyroidism
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+163%
120-day peak, hindsight
Typical move
5.3%
average across 7 past catalysts
Cash runway
~55 mo
Minimal dilution risk
Lead asset
MBX 4291
Phase 1 · Obesity